Prodways Group is positioned across the entire 3D printing value chain, from designing machines and materials through to supplying 3D-printed parts.
Over the last year, Prodways Group has been developing vertical applications using 3D printing, in order to get closer to end customers and their specific requirements. Accordingly, in March 2016, Prodways Group launched PODO3D - a subsidiary dedicated to 'wearable' biomedical equipment. The aim is to deeply transform the orthopaedic insole market with its ScientiFeet product range.
Thanks to 3D printing, ScientiFeet brings a new value proposition to the market, serving podiatry professionals:
- a profitable solution, a product that stands out from the competition, very popular with patients;
- added value for practitioners in terms of patient diagnosis, and savings in time through outsourced production.
Whether orthopaedic, in response to a medical condition, for comfort or to improve sports performance, insoles today represent a growing global market driven by underlying trends:
- social: rapidly increasing practice of sports (walking and running, etc.), greater attention to well-being and health through preventative measures;
- health: prevalence of diabetes and obesity, as well as chronic back pain;
- demographic: an ageing population.
The process of manufacturing a 3D insole is broken down into five distinct stages: the patient's diagnosis by the practitioner, scanning the patient's foot, the 3D digital modelling and ordering of the pair of insoles, and the printing and dispatch of said insoles.
The insoles are 3D-printed by the Prodways Group PRODUCTS division using selective laser sintering technology. Once the production has been finalised, the pairs are delivered to the practitioner's office, who hands them over to the patients. After a 12-month trial period, the solution has been marketed since January 2017.
ScientiFeet is already being used by some 50 regular customers and several dozens of pairs of insoles are manufactured daily. More than 4,000 pairs of ScientiFeet insoles have already been printed.
ScientiFeet will be presented at the 21st podiatry trade fair (Parc Floral de Paris, Château de Vincennes, stand number 51) to be held in Paris on 31 March 2017 and 1 April 2017.
GROUPE GORGE press releases may contain forward-looking statements regarding GROUPE GORGE's targets. These forward-looking statements reflect GROUPE GORGE's current expectations. Such forward-looking statements and targets depend on known and unknown risks, uncertainties and other factors that could cause actual results, performance or events to differ materially from those anticipated herein. The risks and uncertainties that could affect the Group's future ability to achieve its targets include, in addition to those indicated in the press release: the strength of competition; the development of markets in which the Group operates and notably the 3D printing division; currency fluctuations; obtaining the export authorizations that may be required for certain activities; control of costs and expenses; changes in tax legislation, laws, regulations or their enforcement; our ability to successfully keep pace with technological advances; our ability to attract and retain qualified personnel and key staff; the evolution, interpretation and uniform application and enforcement of International Financial Reporting Standards (IFRS), according to which we prepare our FINANCIAL statements; manufacturing and supply chain bottlenecks; the performance of our business partners (subcontractors, agents, suppliers, etc.). Some of these risk factors are set forth and detailed in our Document de Référence (Registration Document including the annual financial report filed with the French Autorité des Marchés Financiers), available on our website www.groupe-gorge.com. This list of risks, uncertainties and other factors is not limitative. Other unanticipated, unknown or unforeseeable factors, such as changes in the economic situation or financial markets, could also have a material adverse effect on our targets.
This press release and the information it contains do not constitute an offer to sell or to subscribe, or a solicitation to purchase or subscribe shares or securities in GROUPE GORGE or in its listed subsidiaries in any country whatsoever.
Follow us on Twitter for live updates from Groupe Gorgé!
About Groupe Gorgé
Groupe Gorgé is an independent group that specializes in high-tech industries. Today, the Group is active in the fields of security and protection in extreme environments, as well as in the 3D printing sector. It employs around 1,700 people, is located in eight countries and directly exports around 40% of its activity. In its more than twenty-five year history, Groupe Gorgé has always developed and driven the latest technological and industrial innovations.
Smart Safety Systems: Developing complete, innovative technological solutions for complex missions in hostile and confined environments.
Protection of High-Risk Installations: Protecting people and ensuring the active and passive protection of installations for energy markets and industrial and tertiary sectors in France. Ensuring the maintenance of these protection systems.
3D Printing: Enabling major industry players to find new routes to successful innovation and production processes by providing systems, 3D printers and new premium material.
In 2016, the Group reported revenue of €281.2 million. It is backed by 1,800 employees and operations in over ten countries.
More information available on www.groupe-gorge.com
Groupe Gorgé is listed on Euronext Paris and on the US OTC market in the form of ADR.
isin code: FR0000062671
Ticker code: GOE
|US OTC market:
CUSIP NUMBER: 399451 103
ISIN NUMBER: US3994511034
Ticker Code: GGRGY / GGRGF
Finance News – Natacha MORANDI – Analysts/Investors Relations - Tel.: +33 1 53 67 36 94 - E-mail: email@example.com
Finance News – Jean-Michel MARMILLON – Press Relations - Tel.: +33 1 53 67 36 73 - E-mail: firstname.lastname@example.org
Image 7 – Lauranne Guirlinger – Press relations – Tel: +33 1 53 70 74 18 – E-mail: email@example.com